A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

2008 ◽  
Vol 24 (8) ◽  
pp. 2173-2179 ◽  
Author(s):  
Mark Speakman ◽  
Vik Khullar ◽  
Anthony Mundy ◽  
Isaac Odeyemi ◽  
John Bolodeoku
Keyword(s):  
Overactive Bladder ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Overactive Bladder Syndrome ◽  
Utility Analysis ◽  
Once Daily

scholarly journals Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome

2021 ◽  
Vol 18 (16) ◽  
pp. 8743
Author(s):  
Habiba Shabir ◽  
Sana Hashemi ◽  
Moussa Al-Rufayie ◽  
Tayo Adelowo ◽  
Umar Riaz ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Cost Effective ◽  
Time Frame ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Overactive Bladder Syndrome ◽  
Utility Analysis ◽  
Net Benefit ◽  
First Line ◽  
Life Years

Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CUA) to compare the medications. Methods: we compared the two treatments in quality-adjusted life years (QALYS), through the NHS’s perspective. Costs were obtained from UK-based sources and were discounted. Total costs were determined by adding the treatment cost and management cost for complications on each branch. A 12-month time frame was used to model the data into a decision tree. Results: Our results found that using Botox first-line had greater cost utility than oxybutynin. The health net benefit calculation showed an increase in 0.22 QALYs when Botox was used first-line. Botox also had greater cost-effectiveness, with the exception of pediatric patients with an ICER of £42,272.14, which is above the NICE threshold of £30,000. Conclusion: Botox was found to be more cost-effective than antimuscarinics in the management of OAB in adults, however less cost-effective in younger patients. This predicates the need for further research to ascertain the age at which Botox becomes cost-effective in the management of OAB.

scholarly journals Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD

2011 ◽  
Vol 105 (11) ◽  
pp. 1635-1647 ◽  
Author(s):  
David Price ◽  
Alastair Gray ◽  
Rupert Gale ◽  
Yumi Asukai ◽  
Laura Mungapen ◽  
...  
Keyword(s):  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Once Daily
Sign in / Sign up

Export Citation Format

Share Document